耐曲伐沙星金黄色葡萄球菌中的拓扑异构酶突变
Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus.
作者信息
Fitzgibbon J E, John J F, Delucia J L, Dubin D T
机构信息
Department of Molecular Genetics and Microbiology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway, New Jersey 08854-5635, USA.
出版信息
Antimicrob Agents Chemother. 1998 Aug;42(8):2122-4. doi: 10.1128/AAC.42.8.2122.
Abstract
A total of 201 Staphylococcus aureus isolates were surveyed for susceptibility to ciprofloxacin and trovafloxacin. Of 66 methicillin-resistant isolates, 89% were ciprofloxacin resistant and 6% were also trovafloxacin resistant. Trovafloxacin-resistant strains had unusual patterns of quinoline resistance mutations in DNA topoisomerase genes, including two mutations in the A subunit (encoded by grlA) of topoisomerase IV.
摘要
共对201株金黄色葡萄球菌分离株进行了环丙沙星和曲伐沙星敏感性检测。在66株耐甲氧西林的分离株中，89%对环丙沙星耐药，6%同时对曲伐沙星耐药。耐曲伐沙星菌株在DNA拓扑异构酶基因中具有不寻常的喹啉耐药突变模式，包括拓扑异构酶IV的A亚基（由grlA编码）中的两个突变。
相似文献
1
Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus.耐曲伐沙星金黄色葡萄球菌中的拓扑异构酶突变
Antimicrob Agents Chemother. 1998 Aug;42(8):2122-4. doi: 10.1128/AAC.42.8.2122.
2
Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.曲伐沙星与其他氟喹诺酮类药物对金黄色葡萄球菌纯化的拓扑异构酶以及gyrA和grlA突变体的活性比较。
Antimicrob Agents Chemother. 1999 Aug;43(8):1845-55. doi: 10.1128/AAC.43.8.1845.
3
Topoisomerase sequences of coagulase-negative staphylococcal isolates resistant to ciprofloxacin or trovafloxacin.对环丙沙星或曲伐沙星耐药的凝固酶阴性葡萄球菌分离株的拓扑异构酶序列
Antimicrob Agents Chemother. 1999 Jul;43(7):1631-7. doi: 10.1128/AAC.43.7.1631.
4
Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.新型氟喹诺酮曲伐沙星（CP-99,219）对体外筛选的肺炎链球菌DNA旋转酶和拓扑异构酶IV突变体的活性。
Antimicrob Agents Chemother. 1996 Dec;40(12):2691-7. doi: 10.1128/AAC.40.12.2691.
5
Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement.喹诺酮类药物对金黄色葡萄球菌拓扑异构酶IV的作用：DNA切割增强的基础。
Biochemistry. 2000 Mar 14;39(10):2726-32. doi: 10.1021/bi992302n.
6
Association of mutations in grlA and gyrA topoisomerase genes with resistance to ciprofloxacin in epidemic and sporadic isolates of methicillin-resistant Staphylococcus aureus.耐甲氧西林金黄色葡萄球菌流行株和散发株中grlA和gyrA拓扑异构酶基因突变与环丙沙星耐药性的关联
Antimicrob Agents Chemother. 1997 Sep;41(9):2023-5. doi: 10.1128/AAC.41.9.2023.
7
Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.拓扑异构酶IV中的喹诺酮耐药性突变：与flqA位点的关系以及金黄色葡萄球菌中拓扑异构酶IV是氟喹诺酮类药物的主要靶点而DNA回旋酶是次要靶点的遗传学证据。
Antimicrob Agents Chemother. 1996 Aug;40(8):1881-8. doi: 10.1128/AAC.40.8.1881.
8
Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.肺炎链球菌中拓扑异构酶IV和DNA促旋酶突变对新型氟喹诺酮类药物耐药性的影响
Antimicrob Agents Chemother. 1999 Aug;43(8):2000-4. doi: 10.1128/AAC.43.8.2000.
9
Topoisomerase mutations in fluoroquinolone-resistant and methicillin-susceptible and -resistant clinical isolates of Staphylococcus aureus.耐氟喹诺酮且对甲氧西林敏感及耐药的金黄色葡萄球菌临床分离株中的拓扑异构酶突变
Antimicrob Agents Chemother. 1998 Jan;42(1):197-8. doi: 10.1128/AAC.42.1.197.
10
Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC.116株不相关金黄色葡萄球菌分离株中grlA、grlB、gyrA和gyrB基因突变特征及突变对环丙沙星最低抑菌浓度的影响
Antimicrob Agents Chemother. 1998 May;42(5):1249-52. doi: 10.1128/AAC.42.5.1249.
引用本文的文献
1
Clonal Lineages, Antimicrobial Resistance, and PVL Carriage of Associated to Skin and Soft-Tissue Infections from Ambulatory Patients in Portugal.葡萄牙门诊患者皮肤和软组织感染相关的克隆谱系、抗菌药物耐药性及杀白细胞素携带情况
Antibiotics (Basel). 2021 Mar 24;10(4):345. doi: 10.3390/antibiotics10040345.
2
Genomics accurately predicts antimicrobial resistance in Staphylococcus pseudintermedius collected as part of Vet-LIRN resistance monitoring.基因组学准确预测了 Vet-LIRN 耐药监测中收集的中间葡萄球菌的抗菌药物耐药性。
Vet Microbiol. 2021 Mar;254:109006. doi: 10.1016/j.vetmic.2021.109006. Epub 2021 Feb 4.
3
Strategic Moves of "Superbugs" Against Available Chemical Scaffolds: Signaling, Regulation, and Challenges.“超级细菌”对现有化学骨架的策略性应对：信号传导、调控及挑战
ACS Pharmacol Transl Sci. 2020 Apr 13;3(3):373-400. doi: 10.1021/acsptsci.0c00005. eCollection 2020 Jun 12.
4
Studies on the antimicrobial properties of N-acylated ciprofloxacins.N-酰化环丙沙星的抗菌性能研究。
Bioorg Med Chem Lett. 2012 Oct 15;22(20):6513-20. doi: 10.1016/j.bmcl.2012.05.026. Epub 2012 Jul 1.
5
Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.人型支原体DNA促旋酶（gyrA）基因的克隆、核苷酸序列分析及体外筛选的曲伐沙星耐药突变株的特性研究
Antimicrob Agents Chemother. 2000 Oct;44(10):2719-27. doi: 10.1128/AAC.44.10.2719-2727.2000.
6
Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesis.金黄色葡萄球菌中拓扑异构酶IV和DNA促旋酶的选择性靶向作用：喹诺酮类药物诱导的DNA合成抑制的不同模式
Antimicrob Agents Chemother. 2000 Aug;44(8):2160-5. doi: 10.1128/AAC.44.8.2160-2165.2000.
7
Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.曲伐沙星与其他氟喹诺酮类药物对金黄色葡萄球菌纯化的拓扑异构酶以及gyrA和grlA突变体的活性比较。
Antimicrob Agents Chemother. 1999 Aug;43(8):1845-55. doi: 10.1128/AAC.43.8.1845.
8
Topoisomerase sequences of coagulase-negative staphylococcal isolates resistant to ciprofloxacin or trovafloxacin.对环丙沙星或曲伐沙星耐药的凝固酶阴性葡萄球菌分离株的拓扑异构酶序列
Antimicrob Agents Chemother. 1999 Jul;43(7):1631-7. doi: 10.1128/AAC.43.7.1631.
本文引用的文献
1
Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus.喹诺酮类药物对从金黄色葡萄球菌中纯化的DNA回旋酶和拓扑异构酶IV的抑制活性。
Antimicrob Agents Chemother. 1997 Nov;41(11):2362-6. doi: 10.1128/AAC.41.11.2362.
2
DNA gyrase, topoisomerase IV, and the 4-quinolones.DNA 回旋酶、拓扑异构酶IV与4-喹诺酮类药物。
Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92. doi: 10.1128/mmbr.61.3.377-392.1997.
3
The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria.新型氟喹诺酮类药物曲伐沙星对革兰氏阳性菌的体外活性。
J Antimicrob Chemother. 1997 Jun;39 Suppl B:57-62. doi: 10.1093/jac/39.suppl_2.57.
4
Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.曲伐沙星（CP-99,219）对445株来自心内膜炎患者和其他血流感染患者的革兰氏阳性分离株的体外活性比较
Antimicrob Agents Chemother. 1997 May;41(5):1146-9. doi: 10.1128/AAC.41.5.1146.
5
Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae.肺炎克雷伯菌喹诺酮耐药临床分离株中DNA促旋酶的GyrA亚基和拓扑异构酶IV的ParC亚基的改变。
Antimicrob Agents Chemother. 1997 Mar;41(3):699-701. doi: 10.1128/AAC.41.3.699.
6
Trends in bacterial resistance to fluoroquinolones.氟喹诺酮类药物的细菌耐药性趋势。
Clin Infect Dis. 1997 Jan;24 Suppl 1:S67-73. doi: 10.1093/clinids/24.supplement_1.s67.
7
Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin.耐环丙沙星葡萄球菌和肠球菌对曲伐沙星的敏感性
Diagn Microbiol Infect Dis. 1996 Sep;26(1):17-21. doi: 10.1016/s0732-8893(96)00146-0.
8
Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus.耐甲氧西林金黄色葡萄球菌喹诺酮耐药临床分离株中gyrA和grlA基因的突变
J Antimicrob Chemother. 1996 Sep;38(3):543-6. doi: 10.1093/jac/38.3.543.
9
Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli.关于parC突变在大肠杆菌高水平氟喹诺酮耐药性形成中作用的遗传学证据。
Antimicrob Agents Chemother. 1996 Apr;40(4):879-85. doi: 10.1128/AAC.40.4.879.
10
Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus.负责金黄色葡萄球菌喹诺酮耐药性的DNA拓扑异构酶IV grlA基因的改变。
Antimicrob Agents Chemother. 1996 May;40(5):1157-63. doi: 10.1128/AAC.40.5.1157.
Zotero 插件